Notably, interventions targeting the CXCR4–SDF1 axis, such as siSDF1, siCXCR4, or antibodies, can downregulate the expression of AGR2, thus suppressing the growth and metastatic potential of PNET cells. Here, AGR2 is linked to primitive neuroectodermal tumor.